
Multi Na-Based Influenza VaccinesAward last edited on: 1/19/2021
Sponsored Program
STTRAwarding Agency
NIH : NIAIDTotal Award Amount
$272,223Award Phase
1Solicitation Topic Code
-----Principal Investigator
Sang-Moo KangCompany Information
Advac LLC
873 Misty View Court
Lilburn, GA 30047
Lilburn, GA 30047
(770) 686-8255 |
N/A |
N/A |
Research Institution
----------
Phase I
Contract Number: 1R41AI152800-01Start Date: 4/20/2020 Completed: 3/31/2021
Phase I year
2020Phase I Amount
$272,223Public Health Relevance Statement:
Narrative Influenza virus causes significant public concerns due to seasonal morbidity and mortality as well as pandemic threat, and thus this application aims to develop effective cross protective vaccines and vaccination. Novel approaches of enhancing the cross protective efficacy of universal vaccines containing consensus conserved multi-epitopes will be highly translational to the clinic, resulting in significant and sustained impact on improving public health. Successful completion of this one-year project will provide the necessary data to enable late preclinical development of this vaccine.
Project Terms:
Animal Model; Animals; Antiviral Agents; B-Lymphocyte Epitopes; Baculoviruses; base; Cell surface; Cells; Centers for Disease Control and Prevention (U.S.); Cessation of life; Chickens; Clinic; Collaborations; Consensus; Data; Development; Disease; Drug Targeting; efficacy study; Epidemic; Epitopes; experience; Extracellular Domain; Ferrets; flu; Flu virus; Funding Mechanisms; Future; Glycoproteins; Hemagglutinin; Human; Immune; Immune response; Immunity; immunogenic; immunogenicity; improved; Influenza; Influenza vaccination; influenza virus vaccine; influenzavirus; Life Cycle Stages; M2 protein; Modeling; Morbidity - disease rate; mortality; mouse model; Mus; Neuraminidase; novel strategies; Outcome; pandemic disease; particle; Phase; phase 2 study; Pilot Projects; pre-clinical; preclinical development; product development; protective efficacy; Proteins; Public Health; Recombinants; Research Personnel; Role; seasonal influenza; Sequence Alignment; Small Business Technology Transfer Research; T-Lymphocyte; Tandem Repeat Sequences; Testing; universal influenza vaccine; universal vaccine; Vaccination; vaccine candidate; vaccine development; vaccine efficacy; vaccine-induced immunity; Vaccines; Variant; vector; Virion; Virus; Virus-like particle
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00